Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of inhaled treprostinil in fibrotic lung disease
2023-504471-25-00Phase 3Authorised
- Sponsor
- United Therapeutics Corporation
- Start
- Mar 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 18
01
Overview
Phase 3, open-label, single-arm trial of treprostinil in idiopathic pulmonary fibrosis (IPF) and pulmonary fibrosis (PF), sponsored by United Therapeutics Corporation. Primary endpoints: Change in absolute forced vital capacity, Time to clinical worsening and 11 more. Planned start Mar 2024; status: authorised.
02
Drugs
treprostinil
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on 2023-504471-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504471-25-00.